June 2011. Volume 7. Number 2

Omalizumab improves asthma control in patients with moderate to severe allergic asthma

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Rodrigo GJ, Neffen H, Castro-Rodríguez JA. Efficacy and safety of subcutaneous omalizumab vs. placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011;139:28-35.
Reviewers: Rivas Juesas C1, Gimeno Díaz de Atauri Á2.
1Servicio de Pediatría. Hospital de Sagunto. Valencia. España.
2Servicio de Pediatría. Hospital Puerta de Hierro. Madrid. España.
Correspondence: Cristina Rivas Juesas. Email: crisrijue@hotmail.com
Reception date: 15/04/2011
Acceptance date: 09/05/2011
Publication date: 01/06/2011

Abstract

Authors' conclusion: in allergic patients with moderate-severe persistent asthma, omalizumab reduces asthma exacerbations and corticosteroids without significant side effects in the short term.

Reviewers' comentary: omalizumab shows efficacy in patients with moderate to severe asthma. Adverse effects reported in trials were local reactions and anaphylaxis. More studies will be needed to assess the long term effects, especially in paediatrics patients.

How to cite this article

Rivas Juesas C, Gimeno Díaz de Atauri A. El omalizumab mejora el control del asma alérgica moderada y grave. Evid Pediatr. 2011;7:46.

AVC | Critically appraised articles

Rodrigo GJ, Neffen H, Castro-Rodríguez JA. Efficacy and safety of subcutaneous omalizumab vs. placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011;139:28-35.
Reviewers: Rivas Juesas C1, Gimeno Díaz de Atauri Á2.
1Servicio de Pediatría. Hospital de Sagunto. Valencia. España.
2Servicio de Pediatría. Hospital Puerta de Hierro. Madrid. España.
Correspondence: Cristina Rivas Juesas. Email: crisrijue@hotmail.com
Reception date: 15/04/2011
Acceptance date: 09/05/2011
Publication date: 01/06/2011

How to cite this article

Rivas Juesas C, Gimeno Díaz de Atauri A. El omalizumab mejora el control del asma alérgica moderada y grave. Evid Pediatr. 2011;7:46.

References

  1. European Medicines Agency (EMEA). Assessment report for Xolair. EMEA/493707/2009. London: EMEA ;2009
  2. US Food and Drug Administration. Early communication about an ongoing safety review of omalizumab (marketed as Xolair). Federal Drug Administration advisory for omalizumab [fecha de publicación: 16-VII-2009] [fecha de consulta: 8-V-2011]. Disponible en: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm172218.htm?sms_ss=email&at_xt=4d91ffc721cf3461%2C0
  3. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention [fecha de actualización: 2010] [fecha de consulta: 8-V-2011].  Disponible en: http://www.ginasthma.com/Guidelineitem.asp??l1=2&l2=1&intId=60
  4. NICE technology appraisal guidance 133 2010. Omalizumab for severe persistent allergic asthma [fecha de publicación: IX-2007] [fecha de actualización: VIII-2010] [fecha de consulta: 8-V-2011]. Disponible en:  http://www.nice.org.uk/nicemedia/live/11894/38392/38392.pdf
  5. NICE technology appraisal guidance 201 2010. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years. Disponible en: http://www.nice.org.uk/nicemedia/live/13256/51345/51345.pdf
  6. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006,19;(2):CD003559.
  7. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol. 2004;114(2):265-9.
01/06/2011

Linked Comment